Email sent September 2, 2020
Dear Friends of Michigan Medicine,
I’m pleased to share with you that Michigan Medicine is partnering with the pharmaceutical company AstraZeneca for a phase 3 clinical trial to test a vaccine against COVID-19. U-M will begin recruiting hundreds of participants for the trial immediately, until the trial is full.
The AZD1222 COVID-19 VACCINE Study will research an investigational vaccine for the prevention of COVID-19, the disease caused by the new coronavirus (SARS-CoV-2). The study will look at how well the investigational vaccine works and how safe it is. U-M is one of several U.S. sites supporting the AstraZeneca trial, with the aim of including 30,000 individuals over a period of two years. We are hopeful that this clinical trial will provide greater answers about the effectiveness and safety of this vaccine in order to save lives. In addition, we are currently in talks with other partners to participate in additional COVID-19 vaccine trials.
The AstraZeneca trial is one of several vaccine trials being funded through a public/private partnership under the U.S. Department of Health and Human Services called Operation Warp Speed. Phase 1/2 trials of the vaccine in more than 1,000 people were completed earlier this year and demonstrated increased antibody responses against SARS-CoV-2 and no serious adverse effects.
As an academic medical center, we are thoroughly supportive of this phase 3 clinical trial and will participate fully in the hopes of positive outcomes. Learn more about the study on the trial web page, or email AZVaccineTrial@med.umich.edu for further information.
Mental health during challenging times
Please join the next installment of our webinar series Well Aware with Michigan Medicine, where experts will discuss mental health in the time of COVID-19. They will share tips for improving emotional wellness in ourselves and our families, including children. The webinar will begin at 1 p.m. on Thursday, September 10. Learn more and register online.
As always, thank you for your support of Michigan Medicine and our endeavors to advance human health.
Marschall S. Runge, M.D., Ph.D.
Dean, University of Michigan Medical School
Executive Vice President for Medical Affairs, U-M
CEO, Michigan Medicine